UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549
                          ---------------------------


                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(D) OF THE
                        SECURITIES EXCHANGE ACT OF 1934


                               SEPTEMBER 14, 2004
                Date of Report (Date of earliest event reported)


                          DISCOVERY LABORATORIES, INC.
             (Exact name of Registrant as specified in its charter)


         DELAWARE                   000-26422                94-3171943
      (State or other       (Commission File Number)        (IRS Employer
       jurisdiction                                    Identification Number)
     of incorporation)


                           350 MAIN STREET, SUITE 307
                         DOYLESTOWN, PENNSYLVANIA 18901
                    (Address of principal executive offices)


                                 (215) 340-4699
              (Registrant's telephone number, including area code)


         (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[_]  Written communications pursuant to Rule 425 under the Securities Act
     (17 CFR 230.425)
[_]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act
     (17 CFR 240.14a-12)
[_]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))
[_]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))



ITEM 5.02.  DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF
            DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS

On September 14, 2004, Discovery Laboratories, Inc. (the "Company") appointed W.
Thomas Amick to its Board of Directors.  Prior to his appointment as a member of
the Board,  Mr. Amick served as a  commercialization  strategist  to the Company
since March 1, 2004.  In such role,  Mr. Amick  received  cash  compensation  of
$60,000  and options to purchase  25,000  shares of common  stock of the Company
pursuant to the terms and  conditions of the Company's 1998 Amended and Restated
Stock Incentive Plan. The Company issued a press release  announcing Mr. Amick's
appointment  on September  14, 2004.  The full text of the press  release is set
forth in Exhibit 99.1 hereto.


ITEM 9.01.  FINANCIAL STATEMENTS AND EXHIBITS

            (c)   Exhibits:

            99.1  Press Release dated September 14, 2004.


                                       2


                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.



                                          DISCOVERY LABORATORIES, INC.


                                          By:   /s/ Robert J. Capetola,
                                              --------------------------------
                                          Name:  Robert J. Capetola, Ph.D.
                                          Title: President and Chief Executive
                                                   Officer

Date: September 20, 2004


                                       3